Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Advocate for Rheumatology with the ACR

From the College  |  November 18, 2015

No one is more qualified than you to tell lawmakers how their policies affect your ability to provide quality care and your patients’ ability to access it. Think your opinion doesn’t matter? Think again.

Thanks to our physician advocates who took the time to call, write, tweet and e-mail their legislators, we have effected change. We played an integral role in the permanent repeal of Medicare’s flawed Sustainable Growth Rate formula; successfully pressured the Centers for Medicare & Medicaid Services to institute safe harbor provisions for ICD-10 implementation; helped reinstate funding for the CDC Arthritis Program; aided in passing biosimilar legislation in more than 10 states; and successfully advocated to the U.S. Food and Drug Administration for biosimilar therapies to have distinguishable names.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

All of this happened in one short year. Although much has been accomplished, we are still working to address many issues—and we need your help. Patients are struggling to avoid the high copayments associated with specialty tiers. Funding for NIH research is nearly 25% less than in 2003 and continues to decline. Unfair and overly restrictive insurer practices are limiting patients’ access to critical treatments and, in some cases, prohibiting rheumatologists from being compensated for the care they provide.

Using the ACR’s new Legislative Action Center (LAC) makes contacting your legislator easier than ever before. From the ACR’s advocacy home page, you can quickly:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  • Access information on legislative initiatives the ACR currently needs your help with;
  • Find the elected officials for your district and their contact information;
  • View and search for legislation; and
  • Share your concerns with your senators and representative using a customizable e-mail template.

We also recommend signing up for alerts on changes to federal and state issues that affect you and your patients. It takes less than two minutes to ensure you will be notified when new advocacy initiatives and updates are available.

Encourage your patients to have a voice in the legislative process, as well. To help your patients be heard, we have designed a special action center just for patients on the ACR’s Simple Tasks website that provides patient-centric overviews of our current issues and all of the same tools available to you for contacting their legislators.

Share: 

Filed under:From the CollegeLegislation & AdvocacyProfessional Topics

Related Articles

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    September 8, 2016

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Should Patients with Rheumatic Disease Switch from Biologic to Biosimilar?

    January 19, 2018

    SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences